Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC)

Austin G. Duffy, Sid P. Kerkar, David E. Kleiner, Susanna V. Ulahannan, Metin Kurtoğlu, Oxana Rusher, Suzanne Fioravanti, Melissa Walker, William D. Figg, Kathryn Compton, Aradhana M. Venkatesan, Nadine Abi‐Jaoudeh, Bradford J. Wood, Tim F. GretenJournal for ImmunoTherapy of Cancer 2014 · DOI

TL;DR

This pilot study explores the safety and preliminary efficacy of combining tremelimumab (an anti-CTLA-4 antibody) with standard ablative therapies (TACE or RFA) for advanced hepatocellular carcinoma (HCC). Early results suggest this combination is feasible and may induce significant immune cell infiltration in tumors, hinting at a promising new therapeutic avenue for HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains a challenging cancer to treat, especially in its advanced stages. While therapies like transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) can offer local control, their ability to induce a systemic anti-tumor immune response is limited. Immunotherapies targeting immune checkpoints, such as CTLA-4, have shown promise in other cancers by unleashing the patient's own immune system against the tumor. However, their application in HCC, particularly in combination with existing ablative techniques, requires careful investigation to assess safety and potential synergistic effects. This paper addresses the critical need to evaluate the feasibility and early immune-modulatory impact of combining tremelimumab with TACE or RFA in HCC patients.

Methods

This was a pilot study designed to assess the safety and preliminary efficacy of tremelimumab in combination with TACE or RFA for patients with advanced HCC. Patients were enrolled and received tremelimumab at one of two dose levels (DL1 and DL2). The study incorporated ablative therapy (TACE or RFA) at week 6 of treatment. Safety was monitored, with a specific focus on dose-limiting toxicities (DLTs) during the first 8 weeks. Tumor tissue was collected at baseline from all patients for analysis. Importantly, on-treatment tumor biopsies were also performed at the time of the radiologic procedure (around week 6) in patients treated at DL2, after DL1 was established as safe. These biopsies were analyzed for immune cell infiltration.

Datasets

Not discussed in the paper. The study involved patient data and tumor biopsies collected during the clinical trial.

Key Insights and Ideas

  • Synergistic Potential: The combination of an immune checkpoint inhibitor (tremelimumab) with local ablative therapies (TACE/RFA) is hypothesized to create a more potent anti-tumor immune response than either treatment alone. Ablative therapies can release tumor antigens, potentially priming the immune system for tremelimumab to then act upon.
  • Immune Cell Infiltration as a Biomarker: The observation of increased immune cell infiltration in post-treatment tumor biopsies from patients receiving tremelimumab is a crucial early indicator of the drug's intended mechanism of action. This suggests the therapy is successfully engaging the immune system within the tumor microenvironment.
  • Feasibility of Combination Therapy: Establishing that this combination therapy is feasible from a safety perspective is a critical first step before larger efficacy studies can be undertaken.

Key Results

  • Patient Cohort: 11 patients with advanced HCC were treated, with 6 at DL1 and 5 at DL2. The cohort comprised 9 males and 2 females, with a median age of 54 years (range 42-75).
  • Treatment Modalities: 4 patients received TACE, and 7 underwent RFA.
  • Immune Response: Preliminary analysis of on-treatment tumor biopsies from 2 out of 5 patients treated at DL2 showed extensive immune cell infiltration after 6 weeks of tremelimumab therapy.
  • Feasibility: The study concluded that tremelimumab in combination with TACE or RFA is feasible in patients with advanced HCC.

Limitations and Future Work

  • Pilot Study Limitations: As a pilot study, the primary limitations are the small sample size (11 patients) and the focus on preliminary safety and feasibility rather than definitive efficacy. The observed immune cell infiltration is a promising signal but needs to be correlated with clinical outcomes.
  • Future Work: The authors state that more in-depth analysis of the tumor biopsies is currently being conducted and will be presented along with comprehensive safety data. This suggests a need for larger, randomized controlled trials to confirm the efficacy of this combination therapy and to further elucidate the immunological mechanisms at play. Understanding the specific types of immune cells infiltrating the tumor and their functional status will be crucial for optimizing treatment strategies.

Summary updated

Abstract

Meeting abstracts Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and results in inhibition of B7-CTLA-4-mediated down regulation of T cell activation. Both transcatheter arterial chemoembolization (TACE) and radiofrequency
BibTeX
@article{duffy2014paired,
  author = {Austin G. Duffy and Sid P. Kerkar and David E. Kleiner and Susanna V. Ulahannan and Metin Kurtoğlu and Oxana Rusher and Suzanne Fioravanti and Melissa Walker and William D. Figg and Kathryn Compton and Aradhana M. Venkatesan and Nadine Abi‐Jaoudeh and Bradford J. Wood and Tim F. Greten},
  title = {{Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC)}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2014},
  doi = {10.1186/2051-1426-2-s3-p98},
}
Figure